Clinical Trials Logo

Clinical Trial Summary

Methadone maintenance therapy (MMT) is one of the modalities to prevent HIV transmission among injected drug users, particularly in opioid-dependent users. However, methadone-associated cardiotoxicity is one of the fatal adverse events that limit the widespread usage in certain groups of opioid-dependent patients. This is a cross-sectional study aimed to investigate the association between 4 KCNH2 SNPs (1539C>T, in exon 6 of KCNH2 gene; 1956T>C, in exon 8 of KCNH2 gene), 2350C>T (in exon 9 of KCNH2 gene), 2690A>C (Exon 11 of KCNH2 gene)) and prolongation of QTc interval in opioid-dependent Kelantanese Malays who are the recipients of Methadone Maintenance Therapy. The investigators hypothesized that subjects with minor alleles of those 4 SNPs will have longer QTc intervals than those with major alleles, adjusting for the effects of other confounding factors such as age and gender of the subjects, plasma methadone trough levels, hypokalemia, hypocalcemia and hypomagnesemia. The investigators also aimed to provide a model that will reliably predict the magnitude QTc based on the SNPs data and other covariates mentioned above. This will greatly assist in identifying methadone recipients who are at risk of developing prolonged QTc or the more fatal torsade de pointes.


Clinical Trial Description

Introduction

Methadone maintenance therapy (MMT) is one of the modalities to prevent HIV transmission among injected drug users, particularly in opioid-dependent users. However, methadone-associated cardiotoxicity is one of the fatal adverse events that limit the widespread usage in certain groups of opioid-dependent patients.

Study hypotheses / aims

The investigators hypothesized that subjects with minor alleles of those 4 SNPs would have longer QTc intervals than those with major alleles, adjusting for the effects of other confounding factors such as age and gender of the subjects, plasma methadone trough levels, hypokalemia, hypocalcemia and hypomagnesemia. The investigators also aimed to provide a model that will reliably predict the magnitude QTc based on the SNPs data and other covariates mentioned above. This will greatly assist in identifying methadone recipients who are at risk of developing prolonged QTc or the more fatal torsade de pointes.

Study Design and Sample Size Calculation

This is a cross-sectional study aimed to investigate the association between 4 KCNH2 SNPs (1539C>T, in exon 6 of KCNH2 gene; 1956T>C, in exon 8 of KCNH2 gene), 2350C>T (in exon 9 of KCNH2 gene), 2690A>C (Exon 11 of KCNH2 gene)) and prolongation of QTc interval in opioid-dependent Kelantanese Malays who are the recipients of Methadone Maintenance Therapy . The sample size was calculated using single-proportion formula and the information required was based on a similar prior study conducted among Singaporean Malay. It was concluded that the sample size required is 105 patients. Since eligible patients were lacking, the convenience (non-probability) sampling method was used.

During the initial visit, relevant clinico-demographic details such as age, gender, history of drug addiction and psychiatric illnesses, drug dependency patterns, other drug usage and treatment-related issues for each patient were gathered. Subsequently a validated Malay version of Subjective Opioid Withdrawal Scale (SOWS) questionnaire was administered to assess any opioid withdrawal symptoms experienced by study participants.

Five (5) mls of blood was then withdrawn for each subject for the ascertainment of relevant biochemical profile (serum potassium, magnesium, calcium), plasma methadone trough levels, and KCNH2 SNPs genotyping. Drug screening for substances such as MDMA, benzodiazepines methamphetamine, cannabis, marijuana were also carried out using urine dipstick test at urine collection point. The colour and temperature of the urine were also recorded.

QT measurement was obtained using calibrated Welch Allyn CP 50™ ECG (Electrocardiograph) (Welch Allyn Australia Pty Ltd., New South Wales, Australia) machine, printed at a paper speed of 25mm/s and voltage of 10mm/mV. QTc measurement was then manually calculated using Fredericia's formula to correct for heart rate (R-R interval). All trained personnel who were responsible for obtaining QTc measurement from each patient were blinded to other information on serum biochemical profiles and methadone trough levels.

KCNH2 Genotyping

The DNA was extracted according to procedures modified from Bethesda Research Laboratories based on the revisions made to the Brinboam and Doly method. The quantity and quality of the extracted DNA were determined using NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Inc. Wilmington, USA) with measurements done at 260 and 280 nm. The integrity of the extracted DNA was determined using 2% agarose gel electrophoresis performed at 70 Volts for 90 minutes.

The DNA in all samples were amplified for all 4KCNH2 SNPs were performed using 2-step nested allele-specific multiplex polymerase chain reaction (PCR). The primers (both forward and reverse) were designed according to the published sequence for KCNH2 (NC_000007.13). To improve primer specificity, mismatch at its 3´ ends that were specific to either the variant sequence or wild-type DNA sequence at the specified locus was made to the primers. Besides, the primers were also designed and manipulated to differentiate between the different single nucleotide changes/alleles during PCR amplification. To verify primers specificity, the BLAST program at NCBI (http://www.ncbi.nlm.nih.gov/ blast) was used.

In the first multiplex PCR, exon 6,8,9 and 11 were amplified under the following condition: pre-denaturation at 95°C for 1 minute followed by 25-cycle of denaturation at 95°C for 15 seconds, annealing for 65°C for 15 seconds, and extension at 72°C for 10 seconds. Upon full 25-cycle completion, final extension phase lasted for 72°C for 7 minutes. The PCR products (amplicons) were then resolved using 2% agarose gel electrophoresis at 130 Volts for 90 minutes.

The PCR products of the first multiplex PCR were then used as templates for second PCR which targeted the 4 respective SNPs region for amplification. This was performed under the following condition:pre-denaturation at 95°C for 1 minute followed by 25-cycle of denaturation at 95°C for 15 seconds, annealing for 69°C for 30 seconds, and extension at 72°C for 4 seconds. Upon full 25-cycle completion, final extension phase lasted for 72°C for 7 minutes. The PCR products (amplicons) were then resolved using 2% agarose gel electrophoresis at 130 Volts for 90 minutes.

The first products of the amplified regions in the Exons 6, 8, 9, and Exon11 were subsequently submitted for direct DNA sequencing. QIAquick PCR purification kit (Qiagen, USA) was used for purification of the PCR products. DNA sequencing was carried out by applying 3130XL genetic analyzer DNA sequencer (ABI, USA). The results were compared with the published sequences for KCNH2 in the NCBI, accession number (NC_000007.13)

Statistical Analysis

The select equally likely or more extreme samples (SELOME) version of the Fisher's exact test was employed to examine whether the distribution of the SNP alleles and genotype follow the Hardy-Weinberg Equilibrium (HWE) assumption. Those SNPs that significantly deviated from the HWE assumption were dropped from further analysis.

To examine the associations between the 4SNPs and QTc interval (measured as continuous variable) and build a statistical model that can reliably predict QTc intervals, simple and multiple linear regression methods were used. Age and gender of the patients, plasma methadone trough levels, serum potassium, calcium and magnesium were treated as confounding factors whose effects on QTc were adjusted for. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03603158
Study type Observational
Source University of Science Malaysia
Contact
Status Completed
Phase
Start date February 1, 2011
Completion date December 31, 2012

See also
  Status Clinical Trial Phase
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02294253 - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone Phase 2/Phase 3
Completed NCT01592461 - Starting Treatment With Agonist Replacement Therapies Follow-up Study N/A
Terminated NCT00768482 - A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence Phase 3
Completed NCT01741350 - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users N/A
Terminated NCT04121546 - Collaborative Care for Opioid Dependence And Pain Pilot Study N/A
Withdrawn NCT03368794 - Naloxone to TReatment Entry in the Emergency Setting N/A
Completed NCT03447743 - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder Early Phase 1
Completed NCT04464421 - SMART Effectiveness Trial N/A
Recruiting NCT04189523 - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage N/A
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Recruiting NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification Phase 2
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Terminated NCT02935101 - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants Phase 2
Completed NCT01895270 - Improving Buprenorphine Detoxification Outcomes With Isradipine Phase 1/Phase 2
Completed NCT01717963 - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway Phase 3
Completed NCT01425060 - Improving Effective Contraceptive Use Among Opioid-maintained Women Phase 1
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4